An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 673 participants.
Also called NCT03514641
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 673 participants
- Sponsor
- Registry
-
NCT03514641
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03514641. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-18 (actual); primary completion 2018-11-30 (actual). Results posted on 2021-09-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct03514641- Content hash
fbe18c88f398f69e2019c36a00ee381a8bb6ba8e12953ed95b38d96a7877645a